Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to prepare to enter phase 3 next month. Lilly showed…
Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors. The deal,…
Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that could net a subsidiary of the artificial intelligence drug discovery…
Eli Lilly has halted development of a phase 2 P2X7 inhibitor for pain, the company confirmed to Fierce Biotech, in the latest shakeup to a pipeline that has already seen…
Eli Lilly and computing giant Nvidia are teaming up to build a new supercomputer that the pair say will be the most powerful owned and operated by a pharmaceutical company.…
Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy. The prize for Lilly is…
While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical trials was expected, the document still raised one…
Eli Lilly is calling on European countries to make “urgent improvements” to their Alzheimer’s disease diagnostic testing practices just weeks after nabbing a new approval on the continent for its…
Eli Lilly is reconsidering plans for its U.K. biotech-focused Gateway Labs, citing concerns about the industry’s outlook in the country and low government spending on new drugs, according to reports…